View Item 

Show simple item record

Prompt, Aggressive BP Lowering in High-Risk Patients
dc.contributor.authorJamerson, Kenneth A.en_US
dc.contributor.authorBasile, Janen_US
dc.date.accessioned2010-06-01T21:07:49Z
dc.date.available2010-06-01T21:07:49Z
dc.date.issued2008-01en_US
dc.identifier.citationJamerson, Kenneth A.; Basile, Jan (2008). "Prompt, Aggressive BP Lowering in High-Risk Patients." The Journal of Clinical Hypertension 10(s1): 40-48. <http://hdl.handle.net/2027.42/74213>en_US
dc.identifier.issn1524-6175en_US
dc.identifier.issn1751-7176en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74213
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18174783&dopt=citationen_US
dc.format.extent479319 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights2008 Le Jacqen_US
dc.titlePrompt, Aggressive BP Lowering in High-Risk Patientsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumFrom the University of Michigan Health Care System, Ann Arbor, MI;en_US
dc.contributor.affiliationotherthe Primary Care Service Line, Ralph H. Johnson VA Medical Center, Charleston, SC;en_US
dc.contributor.affiliationotherthe Division of General Internal Medicine/Geriatrics, Medical University of South Carolina, Charleston, SCen_US
dc.identifier.pmid18174783en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74213/1/j.1524-6175.2007.08145.x.pdf
dc.identifier.doi10.1111/j.1524-6175.2007.08145.xen_US
dc.identifier.sourceThe Journal of Clinical Hypertensionen_US
dc.identifier.citedreference1   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206 – 1252.en_US
dc.identifier.citedreferenceLevine RS, Foster JE, Fullilove RE, et al. Black-white inequalities in mortality and life expectancy, 1933–1999: implications for Healthy People 2010. Pub Health Rep. 2001; 116: 474 – 483.en_US
dc.identifier.citedreferenceSchutta MH. Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J Cardiometab Syndr. 2007; 2: 124 – 130.en_US
dc.identifier.citedreferenceFranklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation. 1999; 100: 354 – 360.en_US
dc.identifier.citedreference5   The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J. 2007; 28: 1462 – 1536.en_US
dc.identifier.citedreferenceDouglas JG, Bakris GL, Epstein M, et al; Hypertension in African Americans Working Group. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163: 525 – 541.en_US
dc.identifier.citedreference7   American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care. 2004; 27 ( suppl 1 ): S65 – S67.en_US
dc.identifier.citedreferenceBakris GL, Williams M, Dworkin L, et al; National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36: 646 – 661.en_US
dc.identifier.citedreferenceJulius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363: 2022 – 2031.en_US
dc.identifier.citedreferenceWeber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004; 363: 2049 – 2051.en_US
dc.identifier.citedreferenceBakris G, Hill M, Mancia G, et al. Achieving blood pressure goals globally: five core actions for health-care professions. A worldwide call to action. J Hum Hypertens. 2007 Aug 30; [Epub ahead of print].en_US
dc.identifier.citedreference12   Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903 – 1913.en_US
dc.identifier.citedreferenceStaessen JA, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003; 21: 1055 – 1076.en_US
dc.identifier.citedreference14   Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000; 355: 1955 – 1964.en_US
dc.identifier.citedreference15   Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003; 362: 1527 – 1535.en_US
dc.identifier.citedreference16   American Heart Association. Heart Disease and Stroke Statistics—2007 Update. Dallas, TX: American Heart Association; 2007.en_US
dc.identifier.citedreferenceFerdinand KC, Saunders E. Hypertension-related morbidity and mortality in African Americans—why we need to do better. J Clin Hypertens (Greenwich). 2006; 8 ( 1 suppl 1 ): 21 – 30.en_US
dc.identifier.citedreferenceBerenson G, Srinivasan S, Chen W, et al; Bogalusa Heart Study Group. Racial (black-white) contrasts of risk for hypertensive disease in youth have implications for preventive care: the Bogalusa Heart Study. Ethn Dis. 2006; 16 ( 3 suppl 4 ): S4-2 – S4-9.en_US
dc.identifier.citedreferenceFerdinand KC, Armani AM. The management of hypertension in African Americans. Crit Pathw Cardiol. 2007; 6: 67 – 71.en_US
dc.identifier.citedreferenceMokwe E, Ohmit SE, Nasser SA, et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Managment Evaluation trial. Hypertension. 2004; 43: 1202 – 1207.en_US
dc.identifier.citedreferenceFlack JM, Mensah GA, Ferrario CM. Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage. Curr Med Res Opin. 2000; 16: 66 – 79.en_US
dc.identifier.citedreferenceMcDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006; 332: 1177 – 1181.en_US
dc.identifier.citedreferenceWeycker D, Nichols GA, O'Keeffe-Rosetti M, et al. Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens. 2007; 20: 599 – 607.en_US
dc.identifier.citedreferenceGress TW, Nieto FJ, Shahar E, et al; Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000; 342: 905 – 912.en_US
dc.identifier.citedreferenceSowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001; 37: 1053 – 1059.en_US
dc.identifier.citedreferenceKabakov E, Norymberg C, Osher E, et al. Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors. J Cardiometab Syndr. 2006; 1: 95 – 101.en_US
dc.identifier.citedreferenceHansson L, Zanchetti A, Carruthers SG, et al; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351: 1755 – 1762.en_US
dc.identifier.citedreference28   UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703 – 713.en_US
dc.identifier.citedreferenceLindholm LH, Ibsen H, DahlÖf B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359 ( 9311 ): 1004 – 1010.en_US
dc.identifier.citedreferenceRussell M, Fleg JL, Galloway J, et al. Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes—the Stop Atherosclerosis in Native Diabetics Study (SANDS). Am Heart J. 2006; 152: 867 – 875.en_US
dc.identifier.citedreferenceCushman WC, Grimm RH Jr, Cutler JA, et al; ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007; 99 ( 12A ): 44i – 55i.en_US
dc.identifier.citedreferenceOng KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007; 49: 69 – 75.en_US
dc.identifier.citedreferenceGiles T, Aranda JM Jr, Suh DC, et al. Ethnic/racial variations in blood pressure awareness, treatment, and control. J Clin Hypertens (Greenwich). 2007; 9: 345 – 354.en_US
dc.identifier.citedreferenceHertz RP, Unger AN, Cornell JA, et al. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med. 2005; 165: 2098 – 2104.en_US
dc.identifier.citedreferenceNeutel JM, Black HR, Weber MA. Combination therapy with diuretics: an evolution of understanding. Am J Med. 1996; 101: 61S – 70S.en_US
dc.identifier.citedreferenceBakris GL, Weir MR; Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003; 5: 202 – 209.en_US
dc.identifier.citedreferenceJamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens. 2004; 17: 495 – 501.en_US
dc.identifier.citedreferenceNeutel JM, Smith DH, Weber MA, et al. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich). 2005; 7: 641 – 646.en_US
dc.identifier.citedreferenceRuilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005; 27: 578 – 588.en_US
dc.identifier.citedreferenceNeutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich). 2006; 8: 850 – 857.en_US
dc.identifier.citedreferencePoldermans D, Glazer R, Karagiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrocholorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007; 29: 279 – 289.en_US
dc.identifier.citedreferencePhilipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007; 29: 563 – 580.en_US
dc.identifier.citedreferenceEstacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338: 645 – 652.en_US
dc.identifier.citedreferenceKjeldsen SE, Aksnes TA, de la Sierra A, et al. Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension. Therapy. 2007; 4: 31 – 40.en_US
dc.identifier.citedreferenceJamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004; 17: 793 – 801.en_US
dc.identifier.citedreferenceDahlÖf B, Sever PS, Poulter NR, et al; ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895 – 906.en_US
dc.identifier.citedreferenceRubio-Guerra AF, Arceo-Navarro A, Lozano-Nuevo JJ, et al. Efficacy of a fixed-dose combination of trandolapril-verapamil in patients with stage 2 hypertension inadequately controlled by monotherapy. Clin Drug Invest. 2005; 25: 445 – 451.en_US
dc.identifier.citedreferenceSmith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of two randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007; 9: 355 – 364.en_US
dc.identifier.citedreferenceChrysant SG, Melino M, Karki S, et al. A randomized, double-blind, placebo-controlled factorial study evaluating the efficacy and safety of co-administration of amlodipine besylate (AML) plus olmesartan medoxomil (OM) compared to monotherapy in patients (PTS) with mild to severe hypertension (HTN) [abstract]. J Clin Hypertens (Greenwich). 2007; 9: 486.en_US
dc.identifier.citedreference50   National Diabetes Education Program. The Diabetes Epidemic Among African Americans Fact Sheet. Bethesda, MD: US Department of Health and Human Services, National Institute of Health; 2005.en_US
dc.identifier.citedreferenceAgodoa LY, Appel L, Bakris GL, et al; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001; 285: 2719 – 2728.en_US
dc.identifier.citedreferenceNiklason A, Hedner T, Niskanen L, et al; CAPPP Study Group. Development of diabetes is retarded by ACE inhibition in hypertensive patients—a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens. 2004; 22: 645 – 652.en_US
dc.identifier.citedreferenceLindholm LH, Ibsen H, Borch-Johnsen K, et al; LIFE Study Group. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study. J Hypertens. 2002; 20: 1879 – 1886.en_US
dc.identifier.citedreferenceAndraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol. 2007; 99: 1006 – 1012.en_US
dc.identifier.citedreferenceAlmgren T, Wilhelmsen L, Samuelsson O, et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens. 2007; 25: 1311 – 1317.en_US
dc.identifier.citedreferenceAksnes TA, Kjeldsen SE, Rostrup M, et al. Impact of new-onset diabetes mellitus on cardiac outcomes in the valsartan antihypertensive long-term use evaluation (VALUE) trial population. Hypertension. 2007; 50: 467 – 473.en_US
dc.identifier.citedreferenceKuti EL, Baker WL, White CM. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker. Curr Med Res Opin. 2007; 23: 1239 – 1244.en_US
dc.identifier.citedreferenceBurke TA, Sturkenboom MC, Ohman-Strickland PA, et al. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. Pharmacoepidemiol Drug Saf. 2007; 16: 979 – 987.en_US
dc.identifier.citedreferenceNawano M, Anai M, Funaki M, et al. Imadapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism. 1999; 48: 1248 – 1255.en_US
dc.identifier.citedreferenceJin HM, Pan Y. Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. Nephrol Dial Transplant. 2007; 22: 1943 – 1949.en_US
dc.identifier.citedreference61   Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MIRCO-HOPE substudy. Lancet. 2000; 355: 253 – 259.en_US
dc.identifier.citedreferenceZandbergen AAM, Baggen MGA, Lamberts SWJ, et al. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. Ann Intern Med. 2003; 139: 90 – 96.en_US
dc.identifier.citedreferenceBuse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007; 115: 114 – 126.en_US
dc.identifier.citedreference64   ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370: 829 – 840.en_US
dc.identifier.citedreferenceJamerson K, Bakris GL, DahlÖf B, et al; ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007; 16: 80 – 86.en_US
dc.identifier.citedreferenceWeber MA, Bakris GL, DahlÖf B, et al; ACCOMPLISH Investigators. Baseline characteristics in the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16: 13 – 19.en_US
dc.identifier.citedreferenceO'Riordan M. ACCOMPLISH at 18 months: better blood-pressure control with single-tablet combination therapy. Heartwire. 2007. http://www.medscape.com/viewarti-cle/557061. Accessed September 27, 2007.en_US
dc.identifier.citedreferenceIwai M, Li HS, Chen R, et al. Calcium channel blocker azelnipidine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmestartan. J Pharmacol Exp Ther. 2006; 319: 1081 – 1087.en_US
dc.identifier.citedreferenceSavoia C, Touyz RM, Endemann DH, et al. Angiotensin receptor blocker added to previous antihypertensive agents on arteries in diabetic hypertensive patients. Hypertension. 2006; 48: 271 – 277.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1524-6175.2007.08145.x.pdf
Size:
468.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.